New analogs of
somatostatin: inhibiting effectively GH, glucagon and insulin levels by Boguslawa Baranowska, Malgorzata Radzikowska, Elzbieta Wasilewska-Dziubinska, Artur
Plonowski, Krzysztof Roguski, Anna Legowska & JŘzef Przybylski
The in vivo effects of three new analogs of somatostatin
(ASS-51, ASS-52 and ASS-53 analogs) on GH, insulin and glucagon were studied in WKY rats.
The solid phase method was used for the synthesis of ASS. Octreotide and ASS were given
iv. in a dose of 0.05 Ķg/kg per animal in a time-dependent manner. ASS-52 and ASS-53 were
longer acting and more potent somatostatin analogs when compared to octreotide in
producing the inhibition of GH. ASS-51 was found to be the most potent and selective
inhibitor of insulin and glucagon release. Our results show that the increased inhibitory
effect and the higher selectivity of the new somatostatin analogs may result from the
differences in their chemical structure.
ASS-52 is most active in inhibiting
GH release. The mechanism by which ASS-52 inhibits preferentially GH release may involve
the opioid system and the activation of GABA-ergic receptors.
In studies in vitro ASS-52 inhibited GH release from pituitary